Werewolf Therapeutics Competitors and Similar CompaniesClear all
Werewolf Therapeutics's competitors and similar companies include Puma Biotechnology, AIM ImmunoTech, Black Diamond Therapeutics and HCW Biologics.
 Werewolf Therapeutics Werewolf Therapeutics is an oncology biotherapeutics company that develops cancer treatments designed to focus the body’s immune response to selectively target cancer. |  Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. |  AIM ImmunoTech AIM ImmunoTech (formerly known as Hemispherx Biopharma) is an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases. |  HCW Biologics HCW Biologics is a company developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell reduction. | ||
Founding Date | Founding Date 2017 | Founding Date 2010 | Founding Date 1990 | Founding Date 2017 | Founding Date 2018 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations Los Angeles, US HQ | Locations Ocala, US HQ New Brunswick, US | Locations Cambridge, US HQ Toronto, CA New York, US Stony Brook, US | Locations Miramar, US HQ |
Employees | Employees 28 | Employees 27214% decrease | Employees 3124% increase | Employees 2456% decrease | Employees 40 |
Valuation ($) | Valuation ($) 118.9 m | Valuation ($) 136.8 m | Valuation ($) 17.1 m | Valuation ($) 165 m | Valuation ($) 16.7 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $228.4m (FY, 2025) | Revenue (est.) $88k (FY, 2025) | Revenue (est.) $70m (FY, 2025) | Revenue (est.) $54.2k (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $58.2m (FY, 2025) | Cost of goods $128k (FY, 2025) | Cost of goods N/A | Cost of goods $43.4k (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $170.2m (FY, 2025) | Gross profit ($40k) (FY, 2025) | Gross profit N/A | Gross profit $10.8k (FY, 2025) |
Net income | Net income ($60.8m) (FY, 2025) | Net income N/A | Net income ($14m) (FY, 2025) | Net income $22.4m (FY, 2025) | Net income ($8m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 56m | Total funding raised $ 172m | Total funding raised N/A | Total funding raised $ 202.1m | Total funding raised $ 24.3m |
For sources of this data, please see the company profile
View Company Profiles
Puma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
View companyAIM ImmunoTech
HQ
Ocala, US
Employees
31↑ 24% increase
AIM ImmunoTech (formerly known as Hemispherx Biopharma) is an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases.
View company
Black Diamond Therapeutics
HQ
Cambridge, US
Employees
24
Black Diamond Therapeutics is a biotechnology company.
View companyHCW Biologics
HQ
Miramar, US
Employees
40
HCW Biologics is a company developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell reduction.
View company